Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction
Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Study Design
Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel group study
Duration: 1 month of TID treatment Treatment Groups, Dosing, and Treatment Regimen Study
Treatment: CBT-008 topical ophthalmic solution Control Treatment: CBT-008 vehicle